All News

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

A collection of hospitals in Rochester, New York, have teamed up to create better access to prescription drugs and combat the city’s pharmacy desert issue.

Patients with type 2 diabetes who had eating problems and higher levels of diabetes distress had worse time-in-range.

Wolters Kluwer Health conducted a survey of just over 1000 respondents to get US adults’ feelings about notable trends in the pharmacy industry.

Researchers aimed to determine the frequency of pain assessments and the extent of pain scores by age for patients undergoing traumatic surgery.

Investigators said there is an imperative to optimize medication utilization and explore the consequences of medication burden on treatment outcomes in patients with long COVID.

Adam J. James, PharmD, joined Drug Topics to discuss his career journey as a chain pharmacist.

Researchers evaluated the efficacy of a self-managed intervention vs enhanced usual care.

Researchers analyzed the impact of the COVID-19 pandemic on outcomes for patients with pancreatic cancer living in England.

Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid."

A conversation with Trent Thiede, PharmD, MBA, president of PAAS National, at NCPA 2024.

Pharmacy experts from AON Pharmacy in Florida discussed the Inflation Reduction Act and how it affects reimbursement for Medicare Part D drugs.

A study found that a continuous glucose monitor workflow led by a pharmacist led to reduced HbA1c levels.

Cassandra Esperant, PharmD, AAHIVP, discussed the ups and downs of her career journey as a clinical HIV pharmacist.

A conversation with AJ Loiacono, co-founder and CEO of Capital RX, at NCPA 2024.

Researchers compared the racial and ethnic representation of participants in food allergen trials with patients who experience food allergies.

Selina Coleman, JD, Partner in Life Sciences Health Industry Group at Reed Smith LLP, discussed recent developments in Supreme Court decisions impacting pharmacy operations.

The data from PURPOSE 2 will be published in The New England Journal of Medicine.

An FDA representative gave a presentation on her organization’s recent updates regarding drug supply chain rules and regulations.

A recent study found that with greater depression severity, metabolic and clinical characteristics such as HbA1c, fasting blood glucose, and triglyceride levels increased.

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

High copayments can be a structural barrier to medication therapy adherence.

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

FDA experts gathered to discuss the DEA’s rescheduling of marijuana and how it will impact the pharmaceutical supply chain.

Lauren Angelo, PharmD, MBA, discusses effective ways pharmacists can educate and encourage their communities on the importance of flu vaccination.

Research has found that children and young adults with overweight or obesity may be at a significantly increased risk of developing long COVID.

Stephen Schondelmeyer, PharmD, PhD, FAPhA, gave a presentation on US drug shortages and their global implications.

A new study found that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.

Joel Ferre, JD, Assistant United States Attorney in Utah, led a discussion covering the DEA and pharmacies’ roles in reporting red flags when dispensing medication.

Check out these important FDA updates from the week of November 4.